Again acquires Genomatica to pair AI discovery with biomanufacturing scale

Again said Aug. 12 that it acquired Genomatica, combining Geno’s AI discovery and design platform with Again’s scale-up and bioprocess engineering capabilities. The deal aims to speed the path from molecule design to industrial manufacturing as biomanufacturing gains momentum in the U.S. and abroad.

Why it matters: - The acquisition brings together AI-driven molecule discovery and real-world biomanufacturing execution in one platform. - Again gains broader capabilities to move products from design to industrial scale faster. - The combined company is positioned to serve a biomanufacturing sector that is pushing for faster deployment across multiple feedstocks. - The deal also comes as reshoring interest in biomanufacturing rises, helped by the U.S. BIOSECURE Act and a $15 billion federal commitment to domestic bio-infrastructure.

What happened: - Again announced Aug. 12 that it acquired Genomatica, also known as Geno. - The companies did not disclose terms of the transaction. - Again described the transaction as one of the most significant consolidations in industrial biotechnology to date. - The acquisition combines Again’s biomanufacturing scale-up capabilities with Geno’s AI discovery and design platform. - Max Kufner, CEO of Again, said the combination is meant to connect AI biology with commercial-scale execution.

The details: - Again is acquiring Geno’s full AI and computational biotech platform. - The assets include Geno’s patent portfolio and data covering experimental results, structural and scale-up insights, and development outcomes. - Geno brings two decades of in silico pathway and strain design experience. - Geno also brings predictive machine learning analytics experience. - Again adds its AI-driven bioprocess design suite and scale-up modeling. - The combined platform is designed to support de novo molecule discovery, pathway design and industrial execution. - Again said the merged company can close the gap between simulation and scaling. - The company said the platform compresses the timeline from de novo pathway design to industrial deployment. - The combined company will operate across the full arc of production, from pathway discovery to industrial-scale manufacturing. - Again said the business will have three value streams: licensing technology, co-developing production pathways and selling products from existing and upcoming assets. - Again said the deal strengthens its commercial and technical offerings for global customers. - Geno, founded in 1998, has commercialized biological processes for widely used chemicals and materials. - Geno says it has built one of the deepest proprietary bioprocess datasets in the industry and a large patent portfolio. - Geno’s technology is used by manufacturers and consumer products companies worldwide. - Again operates in Copenhagen, Munich and Houston. - Again develops technologies for industrial, personal and home care, food and feed markets.

Between the lines: - The deal suggests biomanufacturing is moving from a software-first promise toward an integrated design-and-build model. - AI in biology only creates value if discoveries can be translated into industrial production, making scale-up capability a strategic advantage. - By adding Geno’s data, Again gets a larger training set for its models, which could improve accuracy and shorten development cycles. - The consolidation also points to a more competitive market where platform breadth may matter as much as individual technical breakthroughs.

What's next: - Again said Geno’s technology, IP and commercial footprint will be fully integrated into the Again platform. - Existing Genomatica partners will continue to be supported during the transition. - The combined company will focus on faster deployment across diverse feedstocks and new product pathways. - Again is expected to use the expanded platform to deepen work with global customers and scale its commercial pipeline.

The bottom line: - Again is betting that the next phase of biomanufacturing belongs to companies that can both discover and manufacture at scale.